北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Chromium picolinate supplementation for overweight or obese adults
作者: Tian, Hongliang1; Guo, Xiaohu2; Wang, Xiyu3; He, Zhiyun2; Sun, Rao3; Ge, Sai4; Zhang, Zongjiu3
刊名: COCHRANE DATABASE OF SYSTEMATIC REVIEWS
发表日期: 2013
DOI: 10.1002/14651858.CD010063.pub2
期: 11
收录类别: SCI
文章类型: Review
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: RANDOMIZED CONTROLLED-TRIALS ; TYPE-2 DIABETES-MELLITUS ; RESTING METABOLIC-RATE ; BODY-COMPOSITION ; GLUCOSE-METABOLISM ; OLDER MEN ; WEIGHT ; WOMEN ; METAANALYSIS ; COMBINATION
英文摘要:

Background

Obesity is a global public health threat. Chromium picolinate (CrP) is advocated in the medical literature for the reduction of body weight, and preparations are sold as slimming aids in the USA and Europe, and on the Internet.

Objectives

To assess the effects of CrP supplementation in overweight or obese people.

Search methods

We searched The Cochrane Library, MEDLINE, EMBASE, ISI Web of Knowledge, the Chinese Biomedical Literature Database, the China Journal Fulltext Database and the Chinese Scientific Journals Fulltext Database (all databases to December 2012), as well as other sources (including databases of ongoing trials, clinical trials registers and reference lists).

Selection criteria

We included trials if they were randomised controlled trials (RCT) of CrP supplementation in people who were overweight or obese. We excluded studies including children, pregnant women or individuals with serious medical conditions.

Data collection and analysis

Two authors independently screened titles and abstracts for relevance. Screening for inclusion, data extraction and ′Risk of bias′ assessment were carried out by one author and checked by a second. We assessed the risk of bias by evaluating the domains selection, performance, attrition, detection and reporting bias. We performed a meta-analysis of included trials using Review Manager 5.

Main results

We evaluated nine RCTs involving a total of 622 participants. The RCTs were conducted in the community setting, with interventions mainly delivered by health professionals, and had a short- to medium-term follow up (up to 24 weeks). Three RCTs compared CrP plus resistance or weight training with placebo plus resistance or weight training, the other RCTs compared CrP alone versus placebo.

We focused this review on investigating which dose of CrP would prove most effective versus placebo and therefore assessed the results according to CrP dose. However, in order to find out if CrP works in general, we also analysed the effect of all pooled CrP doses versus placebo on body weight only.

Across all CrP doses investigated (200 mu g, 400 mu g, 500 mu g, 1000 mu g) we noted an effect on body weight in favour of CrP of debatable clinical relevance after 12 to 16 weeks of treatment: mean difference (MD) -1.1 kg (95% CI -1.7 to -0.4); P = 0.001; 392 participants; 6 trials; low-quality evidence (GRADE)). No firm evidence and no dose gradient could be established when comparing different doses of CrP with placebo for various weight loss measures (body weight, body mass index, percentage body fat composition, change in waist circumference).

Only three studies provided information on adverse events (low-quality evidence (GRADE)). There were two serious adverse events and study dropouts in participants taking 1000 mu g CrP, and one serious adverse event in an individual taking 400 mu g CrP. Two participants receiving placebo discontinued due to adverse events; one event was reported as serious. No study reported on all-cause mortality, morbidity, health-related quality of life or socioeconomic effects. Authors′ conclusions We found no current, reliable evidence to inform firm decisions about the efficacy and safety of CrP supplements in overweight or obese adults.

语种: 英语
WOS记录号: WOS:000327587700027
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66909
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Lanzhou Univ, Sch Clin Med 2, Lanzhou 730000, Peoples R China
2.Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Sch Clin Med 1, Lanzhou 730000, Peoples R China
3.Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China
4.Beijing Univ, Beijing Canc Hosp, Beijing 100871, Peoples R China

Recommended Citation:
Tian, Hongliang,Guo, Xiaohu,Wang, Xiyu,et al. Chromium picolinate supplementation for overweight or obese adults[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2013(11).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Tian, Hongliang]'s Articles
[Guo, Xiaohu]'s Articles
[Wang, Xiyu]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Tian, Hongliang]‘s Articles
[Guo, Xiaohu]‘s Articles
[Wang, Xiyu]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace